The classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and mescaline, were used extensively in psychiatry before they were placed in Schedule I of the UN Convention on Drugs in 1967. Experimentation and clinical trials undertaken prior to legal sanction suggest that they are not helpful for those with established psychotic disorders and should be avoided in those liab...

Background Subanesthetic ketamine has accumulated meta-analytic evidence for rapid antidepressant effects in treatment-resistant depression (TRD), resulting both excitement and debate. Many unanswered questions surround ketamine’s mechanisms of action its integration into real-world psychiatric care, diverse utilizations that variously resemble electroconvulsive therapy, conventional antidepres...

Two recent surveys of people who took psychedelic drugs and reported “God experience encounters”, along with successful clinical trials using therapy for depression, have given rise to public misconceptions about psychedelics atheism. Specifically, three inferences been drawn: (1) that the tends dissolve atheist convictions; (2) convictions, once dissolved, are replaced traditional monotheist b...

Abstract There is increasing evidence that psychedelic-assisted psychotherapy effective for a range of psychological conditions. are likely numerous mechanisms action contribute to these clinical effects. One such mechanism might involve psychedelics levels empathic functioning. This paper synthesises research concerning the relationship between and empathy, emphasising neuroscientific contexts...

‘Cyberdelics’ and ‘Cyberdelic Psychotherapy’ have the potential to offer greater precision in modulating entraining therapeutic psychedelic experiences. Both Psychedelics Cyberdelics immerse users enriched sensory landscapes; both been studied as mediums of transformative experience used aids help recovery from mental illness. Psychedelic-assisted therapy (PAT)...

Abstract Despite growing availability of several evidence-based approaches in the treatment substance use disorders, existing pharmacotherapy and psychosocial interventions continue to have significant limitations, such as low retention rates high relapse. There is a need develop new strategies models address these limitations target underlying drivers addiction, motivation change – crucial fac...